Open AccessAllergy to ophthalmic solutions
Author(s) -
Lapeere Hilde,
Veramme Jolien,
De Zaeytijd Julie,
Lambert Jo
Publication year - 2014
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/2045-7022-4-s3-p85
Subject(s) - medicine , ranibizumab , phenylephrine , ophthalmology , anesthesia , refractory (planetary science) , dermatology , surgery , chemotherapy , bevacizumab , physics , astrobiology , blood pressure
Background Ranibizumab (Lucentis) is an antibody fragment with high binding affinity for all isoforms of Vascular Endothelial Growth Factor A (VEGF-A) and is specifically developed for intraocular use. Since its introduction in 2007 it has been administered increasingly and in our hospital approximately 1650 intravitreal injections were given in 2013. Ranibizumab is injected monthly and in most patients for a prolonged period of time. During the procedure several ophthalmic solutions are used, such as local anaesthetic, disinfection, mydriatic drugs and antibiotics.